Substitute for form 1449A/PTO				C	omplete if Known	<u> </u>	·
	<u> </u>			Application Number	09/886,856	0	9
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	June 21, 2001	ENTER	7
				First Named Inventor	Whitehouse	<del>- 30</del>	—ຍາ
				Group Art Unit	1614 1647		
				Examiner Name	Not yet assigned Nich	NS TO	
Cheet	2	of	2	Attorney Docket Number	PP16090.004 (35784/23:		
3							

,,,,,,	**************************************			
	- 2		NON PATENT LITERATURE DOCUMENTS	
DE	Xaminer Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	6	9	FISHER, R.K., and P.L. HARRIS, "Epidemiological and Economic Considerations in the Critically Ischemic Limb," <i>Critical Limb Ischemia</i> , July 1999, pp. 19-25, Futura Publishing Co., New York.	-
	(571)	10	GERWINS, P., et al., "Function of Fibroblast Growth Factors and Vascular Endothelial Growth Factors and Their Receptors in Angiogenesis," Critical Reviews in Oncology/Hematology, 2000, pp. 185-194, Vol. 34(3), Elsevier Science Publishers Ltd., Ireland.	_
	000	11	HIATT, W.R., et al., "Clinical Trials for Claudication - Assessment of Exercise Performance, Functional Status, and Clinical End Points," Circulation, August 1, 1995, pp. 614-621, Vol. 92(3).	_
	(3)	12	LAZAROUS, D.F., et al., "Basic Fibroblast Growth Factor in Patients with Intermittent Claudication: Results of a Phase I Trial," Journal of the American College of Cardiology, October 2000, pp. 1239-1244, Vol. 36(4), Elsevier Science Inc.	_
	(2)	13	PANTELY, G.A., and J.M. PORTER, "Therapeutic Angiogenesis: Time for the Next Phase," Journal of the American College of Cardiology, October 2000, pp. 1245-1247, Vol. 36(4), Elsevier Science Inc.	_
	(2)	14	REGENSTEINER, J.G., et al., "Evaluation of Walking Impairment by Questionnaire in Patients with Peripheral Arterial Disease," <i>Journal of Vascular Medicine and Biology</i> , June 1990, pp. 142-152, Vol. 2(3).	-
	450	15	SANTILLI, J.D., and S.M. SANTILLI, "Chronic Critical Limb Ischemia: Diagnosis, Treatment and Prognosis," <i>American Family Physician</i> , April 1, 1999, pp. 1899-1908, Vol. 59(7).	-
	(22)	16	WEITZ, J.I., et al., "Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review," Circulation, 1996, pp. 3026-3049, Vol. 94.	-
	CSP	17	YANG, H.T., et al., "Basic Fibroblast Growth Factor Increases Collateral Blood Flow in Rats with Femoral Arterial Ligation," Circulation Research, July 1996, pp. 62-69, Vol. 79(1).	
	(3)	18	YANG, H.T., and Y. FENG, "bFGF Increases Collateral Blood Flow in Aged Rats with Femoral Artery Ligation," Am. J. Physiol. Heart Circ. Physiol., 2000, pp. H85-H93, Vol. 278, American Physiological Society, USA.	

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Vol. 278, American Physiological Society, USA.

Physiological Society, USA.

YANG, H.T., et al., "Efficacy and Specificity of bFGF Increased Collateral Flow in Experimental

Peripheral Arterial Insufficiency," Am. J. Physiol. Heart Circ. Physiol., 2000, pp. H1966-H1973,

YANG, H.T., et al., "Exercise Training Enhances Basic Fibroblast Growth Factor-Induced Collateral Blood Flow," Am. J. Physiol. Heart Circ. Physiol., 1998, pp. H2053-H2061, Vol. 274, American

Date

Considered

12/17/02

Examiner

Signature

19

20

~							ipieie ii Kii wn		<u> </u>	
					Ap	plication Number	09/886,856		Ė	
	INFORMATION							i.	2	
		DISCLOSURE				ing Date	June 21, 2001	. 3	<u>₹</u>	
TPE	STATE	STATEMENT BY APPLICANT			First Named Inventor		Whitehouse		ENTER	
2,	6				Group Art Unit					
007 4 0 001	(U	(Use as many sheets as necessary)				aminer Name	Not yet assigned	Nichals &	5 5	
OCT 1 0 200	Sheet	Sheet 1 of 2			—	torney Docket Number	PP16090.004 (35784/235886)			
*	Seet   1   of   2   Attorney Docket Number   PP16090.004 (35784/235886)   Seet   1   of   2   Attorney Docket Number   PP16090.004 (35784/235886)   Seet   1   of   2   Attorney Docket Number   PP16090.004 (35784/235886)   Seet   1   of   2   Attorney Docket Number   PP16090.004 (35784/235886)   Seet   1   of   2   Attorney Docket Number   PP16090.004 (35784/235886)   Seet   1   of   2   Attorney Docket Number   PP16090.004 (35784/235886)   Seet   1   of   2   Attorney Docket Number   PP16090.004 (35784/235886)   Seet   1   of   2   Attorney Docket Number   PP16090.004 (35784/235886)   Seet   1   of   2   Attorney Docket Number   PP16090.004 (35784/235886)   Seet   1   of   2   Attorney Docket Number   PP16090.004 (35784/235886)   Seet   1   of   2   Attorney Docket Number   PP16090.004 (35784/235886)   Seet   1   of   2   Attorney Docket Number   PP16090.004 (35784/235886)   Seet   1   of   2   Attorney Docket Number   PP16090.004 (35784/235886)   Seet   1   of   2   Of   2									
TE TRADE	U. S. PATENT DOCUMENTS									
TRAUCH		1	U.S. Patent Do		<u> </u>	ATENT DOCUMENT	Date of	Pages, Columns, L.	ines,	
	Examiner	Cite No. <sup>1</sup>	Number (if			Name of Patentee or Applicant Of Cited Document		Where Relevant Pass	here Relevant Passages of	
	Initials*				n)		Cited Document	Relevant Figures A	ppear	
	(-)	1	5,604,293			Fiddes et al.	MM-DD-YYYY	1	M	
	C-7/1	<u> </u>					02-18-1997			
	URS	2	5,792,453			Hammond et al.	08-11-1998			
	CON	3	5,852,177	-		Senoo et al.	12-22-1998			
	CSN	4	5,879,713			Roth et al.	03-09-1999			
	CSN	5	5,941,868			Kaplan et al.	08-24-1999			
									<del></del>	
		FOREIGN PATENT DOCUMENTS								
			Foreign Patent D	Ocument			Date of	Pages, Columns, Lines,	T	
	Examiner Initials	Cite No.	Kin Office <sup>3</sup> Number <sup>4</sup> (if kr		- 1		1	Where Relevant Passages or Relevant	T <sup>6</sup>	
	minais	10.	Office Number	(if know	")	Applicant of Cited Document	Cited Document MM-DD-YYYY	Figures Appear		
								<u> </u>	1.	
	-			_					+	
	<del></del>		NON	ID 4 COT	7 70 77 70 70	I IMPD AMERICA NO. CO.	D.GEN/ESS			
	<u> </u>	ſ <u>-</u>				LITERATURE DOCU		Alde - Cale - 1	· —	
	Examiner	Cite	(book, magazine, iou	mal, seria	l, syn	TAL LETTERS), title of the artic apposium, catalog, etc.), date, page	ie (wiien appropriate), (s) , volume-issue num	uue of the item	T	
	Initials No. and/or country where published.					l				
	6 BAFFOUR, R., et al., "Enhanced Angiogenesis and Gro							ivo Administration		
	of Recombinant Basic Fibroblast Growth Factor in a Rabbit Model of Acute Lower Limb Ischemia:  Dose-Response Effect of Basic Fibroblast Growth Factor," Journal of Vascular Surgery, August 1992, pp. 181-191, Vol. 16(2).  BAUMGARTNER, I., and J.M. ISNER, "Stimulation of Peripheral Angiogenesis by Vascular Endothelial Growth Factor (VEGF)," VASA, November 1998, pp. 201-206, Vol. 27(4).  COOKE, J.P., et al., "Fibroblast Growth Factor as Therapy for Critical Limb Ischemia: A Case Report," Vascular Medicine, 1999, pp. 89-91, Vol. 4.  Examiner  Date									
									<del></del>	
	Signature Considered 1211							1217/02	<u>'</u>	
						<del></del>				

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number.

<sup>&</sup>lt;sup>2</sup> See attached Kinds of U.S. Patent Documents.

<sup>&</sup>lt;sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>&</sup>lt;sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

<sup>&</sup>lt;sup>6</sup> Applicant is to place an "X" here if English language Translation is attached.